Table 1 Baseline characteristics of the included studies
Group | Study ID | Country origin | No. of non-catecholamine vasopressors/NE | Age (years) | Female (%) | APACHE II score | Intervention (non-catecholamine vasopressors) | Comparison (NE) | Center | Setting | MAP target (mmHg) |
|---|---|---|---|---|---|---|---|---|---|---|---|
VP | Dunser et al. 2003 [30] | Austria | 8/7 | … | ... | ... | 4.00 U/h | MD 2.26 μg/kg/min | S | ICU | ≥ 70 |
Lauzier et al. 2006 [20] | Multi-country | 13/10 | 54.20 | 39.13 | 23.10 | 0.04–0.20 U/min | 0.10–2.80 μg/kg/min | M | ICU | > 70 | |
Russell et al. 2008 [17] | Multi-country | 397/382 | 60.53 | 39.02 | 27.05 | ID 0.01 U/min MD 0.03 U/min | ID 5.00 μg/min MD 15.00 μg/min | M | ICU | 65–75 | |
Morelli et al. 2009 [26] | Italy | 15/15 | 65.00 | 26.67 | 59.00a | FD 0.03 U/min | FD 15.00 μg/min | S | ICU | 65–75 | |
Fonseca-Ruiz et al. 2013 [21] | Colombia | 14/16 | 57.33 | 40.00 | 19.20 | 0.01–0.04 U /min | ... | M | ICU | ≥ 65 | |
Oliveira et al. 2014 [13] | Brazil | 191/196 | ... | ... | ... | 0.01–0.03 U/min | 0.05–2.00 μg/kg/min | ... | ICU | ... | |
Barzegar et al. 2016 [22] | Iran | 15/15 | 64.00 | 36.67 | ... | FD 0.03 U/min | ... | S | ICU | ≥ 65 | |
Gordon et al. 2016 [18] | England | 205/204 | 66.51 | 41.81 | 23.75 | MD 0.06 U/min | MD 12.00 μg/min | M | ICU | 65–75 | |
Hammond et al. 2018 [23] | America | 41/41 | 61.00 | 51.22 | 25.00 | FD 0.04 U/min | ID 5.00 μg/min MD 15.00 μg/min | S | ICU | ≥ 65 | |
Hajjar et al. 2019 [31] | Brazil | 125/125 | 63.00 | 45.20 | 7.00b | FD 0.01–0.06 U/min | 10.00–60.00 μg/min | S | ICU | ≥ 65 | |
VP analogues | Albanèse et al. 2005 [24] | France | 10/10 | 65.50 | 35.00 | 28.50 | BD 1.00 mg | FD 0.30 μg/kg/min | S | ICU | 65–75 |
Morelli et al. 2008 [25] | Italy | 19/20 | 66.51 | 30.77 | 59.49a | BD 1.00 mg | FD 0.90 μg/kg/min | S | ICU | 65–75 | |
Morelli et al. 2009 [26] | Italy | 15/15 | 65.50 | 23.30 | 60.00a | FD 1.30 μg/kg/h | FD 15.00 μg/min | S | ICU | 65–75 | |
Han et al. 2012 [27] | China | 66/73 | 71.84 | 28.78 | 27.34 | 1.00–2.50 U/ h | ... | M | ICU | ... | |
Svoboda et al. 2012 [16] | Czech Republic | 13/17 | 72.83 | 40.00 | 18.00b | FD 4.00 mg/24 h | ... | S | ICU | 65–75 | |
Xiao et al. 2016 [14] | China | 15/17 | 62.47 | 31.25 | ... | FD 1.30 μg/kg/h | ID 0.5.00 μg/min/kg MD 2.22 μg/min/kg | S | ICU | 65–95 | |
Choudhury et al. 2017 [32] | India | 42/42 | 47.53 | 17.86 | 14.26b | ID 1.30–5.20 μg /min | FD 15.00 μg/min | S | LICU | ≥ 65 | |
Chen et al. 2017 [28] | China | 31/26 | 57.22 | 49.12 | 22.05 | FD 0.01–0.04 U/min | FD > 1.00 μg/min | S | ICU | 65–75 | |
Russell et al. 2017 [11] | Multi-country | 29/21 | 60.10 | 44.00 | 10.48b | FD 1.25/2.50 ng/kg/min | ... | M | ICU | ≥ 65 | |
Prakash et al. 2018 [15] | India | 91/93 | ... | ... | 12.51b | FD 2.00 mg/24 h | 7.50-60.00 μg /min | S | ICU | > 65 | |
Liu et al. 2018 [19] | China | 260/266 | 61.01 | 37.07 | 19.09 | ID 20.00 μg/h MD 160.00 μg/h | ID 4.00 μg /min MD 30.00 μg/min | M | ICU | 65–75 | |
Laterre et al. 2019 [4] | Multi-country | 562/266 | 66.31 | 41.18 | 25.80 | 1.70/2.50/3.50 ng/kg/min | ... | M | ICU | ≥ 65 | |
AT-II | Chawla et al. 2014 [33] | America | 10/10 | 62.85 | 25.00 | 30.60 | ID 20.00 ng/kg/min MD 40.00 ng/kg/min | … | S | ICU | ≥ 65 |
Khanna et al. 2017 [34] | Multi-country | 163/158 | 64.00 | 39.25 | 28.00 | ID 20.00 ng//kg/min MD 200.00 ng//kg/min | … | M | ICU | 65–75 |